Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPO and Hydroxyurea in Sickle Cell Disease
NCT05451940Phase 2Completed
- Start
- May 2023
- Primary completion
- Dec 2024
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of epoetin alfa in anemia. Primary endpoint: Percentage of Participants With Hemoglobin Response at 12 weeks. Started May 2023; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT05451940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451940.